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Foxl2 is a forkhead transcription factor required for ovary development and ovarian follicle mat-
uration. In this report, we identified and characterized a functional relationship between Foxl2
expression and estrogen receptor (ER)- signaling. We show that Foxl2 has no effect on classical
ER-mediated transcription, which occurs through canonical estrogen response elements. How-
ever, Foxl2 suppresses ER signaling through nonclassical tethered transcriptional pathways. Specifi-
cally, the selective ERmodulator tamoxifen stimulates activator protein-1 (AP1)-dependent transcrip-
tion via the ER, and this enhancement is blocked by Foxl2. Two lines of evidence suggest that Foxl2
suppression ismediatedbyphysical interactionswithER rather thandirectactionatAP1bindingsites.
First, ER is coimmunoprecipitated with Foxl2. Second, activation of a upstream activating sequence
(UAS)reporterbyGal4-cJuninthepresenceofERandtamoxifenwasblockedbyFoxl2,demonstrating
suppression in the absence of an AP1 site. Cyclooxygenase-2 (COX2), which is required for ovulation,
was identified through expression profiling as a candidate physiological target for nonclassical ER
signaling and thusmodulation by ER/Foxl2 interactions. This possibilitywas confirmed by two sets of
experiments. COX2 protein levels were induced by ER in the presence of tamoxifen, and protein
expressionwas suppressedby Foxl2. In addition, ER stimulationof theCOX2promoterwas repressed
by Foxl2.We conclude that ER and Foxl2 interact and that Foxl2 selectively suppresses ER-mediated
transcriptionofAP1-regulatedgenes.Thesedataprovideapotentialpointof convergenceforERand
Foxl2 to regulate ovarian development and function. (Endocrinology 150: 5085–5093, 2009)
Estrogen plays an important role in the developmentand differentiation of the reproductive system and in
the function of a number of adult tissues (1). Under most
circumstances, the physiological effects of estrogen are
mediated by the estrogen receptors (ERs), ER and ER
(2, 3). ER andERhave different biological functions, as
indicated by their specific expression patterns, different
target genes, and the distinct phenotypes observed in ER
and ER knockout mice. In the reproductive system, ER
knockout females have a relatively mild phenotype char-
acterized by smaller ovaries, some arrested follicular devel-
opment, anda reducednumberof corpora lutea (4). By com-
parison, ER knockout females are acyclic and infertile and
possess hyperemic ovaries devoid of corpora lutea (1).
In the classical model of ER action, ligand-activated
receptors bind to estrogen response elements (EREs),
where they recruit transcriptional cofactors to activate or
suppress estrogen-responsive genes. In addition, there are
nonclassical pathways, which do not involve EREs. These
include a rapid membrane-associated ER pathway (5), in-
teractions of the ERwith signalingmolecules downstream
of transmembrane receptors (e.g. epithelial growth factor
receptor) (5), and a tethered pathway in which the ER
interacts with other transcription factors bound to their
response elements. In the latter category, ER has been
shown to interactwith activator protein-1 (AP1), SP1, and
nuclear factor-B to transactivate or suppress various
genes (6), and it is likely that ER interacts with other tran-
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scription factors as well. An ER DNA binding domain
mutant that eliminates binding to EREs but retains teth-
ered transcriptional activity has revealed physiologic ac-
tions mediated by nonclassical signaling. These include
estrogen-mediated feedback on the female reproductive
axis (7) and estrogen actions on the testis-associated ducts
inmales (8).However, the specific genes and transcription
factors that mediate the nonclassical physiologic actions
remain unclear.
Foxl2 is a member of the forkhead family of transcrip-
tion factors. Its features include a winged helix domain
important for DNA binding and a conserved polyalanine
tract at the C terminus that is involved in transcriptional
repression (9). Expression of murine Foxl2 has been re-
ported in the embryonic eyelids, pituitary, and follicle cells
of the ovary (10, 11). Consistent with this expression pat-
tern, Foxl2knockoutmice exhibit eyelid/craniofacialmal-
formation in both sexes (11) and impaired ovarian devel-
opment and function (12). Specifically the granulosa cells
of Foxl2 homozygous mutant mice do not complete the
squamous to cuboidal transition, leading to an absence of
secondary follicles, oocyte atresia, and premature ovarian
failure. Sterility in Foxl2 null mice is restricted to females.
Inactivatingmutations in humanFOXL2cause blepha-
rophimosis-ptosis-epicanthus inversus syndrome and af-
fected patients exhibit eyelid malformations that can be
observed with or without premature ovarian failure (type
I or type II, respectively) (13). A FOXL2 missense point
mutation, [402C–G, (C134W)] is also present in 97%of
adult-type granulosa cell tumors of the ovary, suggesting
that it is capable of driving the pathogenesis of these tu-
mors (14). Despite the importance of Foxl2 in ovarian
development, few direct gene targets of Foxl2 are known.
Those that have been identified include the glycoprotein
hormone -subunit, steroidogenic acute regulatory pro-
tein (15), GnRH receptor (16), and aromatase (17). No-
tably, these genes are all important in reproduction.
Foxl2 is expressed in phylogenetically distant verte-
brate groups, including species that have distinct mecha-
nisms of sex determination (18). It is thus considered to be
a highly conserved regulator of ovarian development. In
rainbow trout, FoxL2b is expressed during oocyte entry
into meiosis. Notably, meiotic entry is a hallmark event
that commits embryonic germ cells to the female pathway
in mammals. Of further interest, the female expression
pattern of trout Foxl2a is recapitulated by exposure of the
male gonad to 17-ethynylestradiol (19). In turtles, in
which sex determination is temperature dependent, ER
expression emerges in parallel with Foxl2 as part of a
group of genes in a core ovary-determining pathway (20).
Based on these data, we hypothesized that Foxl2 might
interact with one or more of the ER signaling pathways.
In the present study, we explored this hypothesis in mam-
malian cells.
Materials and Methods
Plasmids
A mouse Foxl2-HA expression vector was created by PCR
amplifying the Foxl2 coding sequence using a 3 primer that
incorporated the hemagglutinin (HA) coding sequence. Primers
were as follows: sense, 5-ATG ATG GCC AGC TAC CCC-3
and antisense, 5-GAT CGC GGC CGC TCA AGC GTA GTC
TGG GAC GTC GTA TGG GTA GAG ATC CAG ACG CGA
GTG-3 (HA coding sequence is underlined). The PCR product
was subcloned into pcDNA3.0 (Invitrogen, Carlsbad, CA)
and sequence verified using GenBank NM_012020 as a ref-
erence. The Gal4-DBD expression vector, Gal4-DBD/c-Jun
expression vector, ERE2-TK109-Luc reporter, AP1-7-Luc re-
porter, 73Col-Luc reporter, and UAS-E1b-TATA-Luc reporter
have been described previously (21). The Cox2-Luc reporter
(pGS459; containing 459/9 from the human Cox2 pro-
moter) was provided by Dr. Lee-HoWang (University of Texas,
Houston, TX).
Cell culture
293FT cells (ER negative human embryonic kidney) and
MDA-MB-231 cells (ER negative human breast cancer; sub-
clone 10A) were cultured at 37 C in a humidified atmosphere of
5% CO2 in DMEM/F12 supplemented with 10% fetal bovine
serum. Four days before transfection, cells were changed to es-
trogen-depleted media, prepared without phenol red, and sup-
plemented with sera extracted three times with dextran-coated
charcoal.
Transfections and luciferase assays
Cells were transferred to 24-well plates in estrogen-depleted
medium 1 d before transfection. 293FT cells were transfected
with calcium phosphate and MDA-MB-231 cells were trans-
fected with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. The ERE, AP1, 73 collagenase,
cyclooxygenase-2 (COX2), and UAS-E1b-TATA-Luc reporter
plasmidswere transfected at a concentration of 500 ng/well. The
ER, mFoxl2, ERAA, and Gal4-c-Jun expression vectors or
emptyvectorpcDNA3.0was transfectedat a concentrationof50
ng/well. 17-Estradiol and tamoxifen (Sigma-Aldrich, St. Louis,
MO) were reconstituted in EtOH and diluted into media at final
concentrations of 1 nM 17-estradiol and 100 nM tamoxifen.
Equal volumes of ethanol alone were added to control wells.
Luciferase activity was determined 48 h after transfection using
a Biotek Clarity luminometer (Winooski, VT).
Western blots
MDA-MB-231and 293FT cells were transfected with the in-
dicated expression vectors and cultured for 2 d in estrogen-de-
pletedmedium.Nuclear and cytoplasmic extractswere prepared
as described previously (22) or using NE-PER nuclear and cy-
toplasmic extraction reagents (Thermo Scientific, Waltham,
MA)according to themanufacturer’s instructions. Extractswere
run on 10% sodium dodecyl sulfate-polyacrylamide gels and
transferred onto Hybond membranes (Amersham Biosciences,
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Piscataway, NJ). Immunodetection was performed using rabbit
polyclonal human COX-2 antibody H-62, mouse monoclonal
human ER antibody D-12 (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit polyclonal Foxl2 antibody PA1–802 (Affinity
Bioreagents, Rockford, IL), and antirabbit or antimouse horse-
radish peroxidase-conjugated IgG. Primary antibodies were di-
luted 1:1000 in 1% nonfat milk containing 1 Tris-buffered
saline and 0.1% Tween 20 and incubated for overnight at 4 C.
Proteins were visualized using an ECL Plus kit (Amersham Bio-
sciences) according to the manufacturer’s instructions.
Immunofluorescence
293FT cells were grown on poly-D-lysine-coated coverslips in
six-well plates and transfectedwith 500 ng of each expression con-
struct using Lipofectamine 2000 (Invitrogen), following the man-
ufacturer’s recommendations. After 48 h, cells were treated with
tamoxifen or vehicle for 1 h, washed in PBS, fixed 10minwith 4%
paraformaldehyde, permeabilized 5minwith 0.1%TritonX-100,
and blocked in 1.5% BSA. Cells transfected with ER were incu-
bated with mouse anti-ER primary at 1:50 in blocking buffer,
followed by goat antimouse-AlexaFluor 568 (Invitrogen) second-
ary at 1:500, whereas cells transfected with Foxl2 were incubated
with rabbit anti-Foxl2 serum at 1:2000 and goat antirabbit-Alex-
aFluor 488 (Invitrogen) secondary at 1:500. Antibody incubations
wereeachperformedfor1hatroomtemperature.Allcellswerealso
stained with 4,6-diamidino-2-phenylindole (DAPI).
Immunoprecipitation
293FT cells were mock transfected or transfected with
Foxl2-HA and ER overnight and then treated for 48 h with
ligands. Extracts were prepared by suspending cells in Nonidet
P-40 lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1%
Nonidet P-40] containingminicomplete protease inhibitormix-
ture (Roche Applied Science, Indianapolis, IN). Protein con-
centrations were measured by the Bradford assay (Bio-Rad,
Hercules, CA). Reactions were started by adding 10l of mouse
preimmune serum. After incubation at 4 C for 30 min, 10 l of
mouse anti-HA (Cell Signaling, Danvers, MA) were added to 400
g of whole-cell extract resuspended in 1 immunoprecipitation
buffer (Sigma) to a total volume of 600 l. Reactions were incu-
batedat4Covernightonarockingtable,30lofproteinA-agarose
was added to each tube, and tubes were again incubated overnight
at4C.After incubation,sampleswerecentrifugedat12,000 g for
30 sec at 4 C, washed six times with 600l of 1 immunoprecipi-
tation buffer, and resuspended in 60l of 1 Laemmli buffer. For
detection of ER, samples were subjected to electrophoresis on
12% sodium dodecyl sulfate-polyacrylamide gels and transferred
onto Hybond membranes. Blots were probed with mouse mono-
clonalERantibodyD-12 (SantaCruz)andantimousehorseradish
peroxidase-conjugated IgG. Proteins were visualized using an ECL
Plus kit according to the manufacturer’s instructions.
Statistical analysis
Individual transfection experiments were carried out in qua-
druplicate, and experiments were repeated two to four times.
Data for each experiment were scaled to the mean of all values
in that experiment before comparison because luminometer
units are relative and vary between experiments. Differences be-
tween treatments were determined using ANOVA followed by
Neumann-Keuls post hoc testing, with a threshold for statistical
significance of P  0.05.
Results
Foxl2 inhibits AP1-dependent, but not
ERE-dependent, ER activity
Reporter constructs were used to determine whether
Foxl2 has activity on, and specificity for, different ER
signaling pathways.On anERE-containing reporter (clas-
sical pathway), 17-estradiol (E2; 1 nM) stimulated activ-
ity 6-fold relative to control in the presence of ER [3.88
vs. 0.64 relative light units (RLU)], whereas tamoxifen
(100 nM) was without effect (Fig. 1A). Foxl2 alone con-
veyed no response to either ligand, nor did it alter the
ER-mediated response to E2.
On an AP1 reporter (nonclassical pathway), E2 was
without effect in the presence of ER (Fig. 1B), but ta-
moxifen stimulated reporter activity 11.3-fold.These data
are consistent with the previous observation that tamox-
ifen acts as an ER agonist at AP1 sites (21). Foxl2 again
conveyed no response to either ligand. Unexpectedly,
however, tamoxifen stimulation of the AP1 reporter
through ER was completely abolished by coexpression
of Foxl2. Thus, Foxl2 selectively represses ER stimula-
tion of a nonclassical estrogen signaling pathway.
FIG. 1. Effect of Foxl2 expression on ERE- and AP1-mediated
transactivation. 293FT cells were transfected with human ER and/or
mouse Foxl2 expression vectors and treated for 24 h with vehicle
control (ethanol), E2, or tamoxifen. A, Response of a reporter construct
containing two copies of the vitellogenin ERE upstream of a 109-bp
fragment of the thymidine kinase promoter. B, Response of a reporter
construct containing multiple AP1 sites upstream of a basal promoter.
Bars, mean  SEM of two to three experiments. *, P  0.05.
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This effect is not a consequence of ER degradation,
which can occur in response to certain stimuli. Overex-
pression of Foxl2 did not alter levels of exogenously ex-
pressed ER protein in 293FT cells or endogenous ER
protein in MCF-7 breast epithelial cells (not shown).
Foxl2 blocks AP1-mediated activity on the native
collagenase promoter
The proximal collagenase promoter (73 to 63),
which contains a single AP1 site, was used to evaluate
whether Foxl2 can act via ER and AP1 in a native pro-
moter context. In the presence of ER, tamoxifen induced
collagenase promoter activity 3.6-fold (Fig. 2A). Expres-
sion of Foxl2 blocked tamoxifen induction, similar to the
results on the synthetic AP1 reporter. E2 had no effect
under these conditions.
To confirm that Foxl2 acts on ER that is not bound
directly to DNA, we used a modified ER (ERAA) that
contains two pointmutations in theDNAbinding domain
(E207A/G208A).Themutations eliminateERbinding to
DNA but preserve ER interactions with other proteins,
including cJun (21). Tamoxifen stimulated collagenase re-
porter activity 5.3-fold via ERAA (Fig. 2B), similar to the
response with WT ER. This activity was suppressed by
Foxl2, confirming that Foxl2 acts on ER that is signaling
via the tethered nonclassical mechanism.
Foxl2 binds to ER
Transcriptional control by Foxl2 and ER was exam-
ined further using a one-hybrid reporter system. In this
assay, a cJun-Gal4hybrid binds to the upstreamactivating
sequence (UAS) recognition sequence to stimulate tran-
scription, allowing cJun-mediated transactivation to be
studied in the complete absence of AP1 or other transcrip-
tion factor recognition sequences (Fig. 3A, schematic).
The Gal4 DNA-binding protein alone was unresponsive
to ligands despite the presence of ER, as expected (Fig.
3A). By comparison, the cJun-Gal4 hybrid conferred ta-
moxifen responsiveness when coexpressed with ER, in-
FIG. 2. Effect of Foxl2 expression on non-ERE-dependent
transactivation of the collagenase promoter. A, 293FT cells were
transfected with human ER and/or mouse Foxl2 expression vectors
and treated for 24 h with vehicle control (ethanol), E2, or tamoxifen.
Response of the 73Col-luciferase reporter is shown. B, Same as panel
A, except the mERAA contains two point mutations in the DNA-
binding domain (E207A/G208A) that preclude binding to DNA. Bars,
mean  SEM of two experiments. *, P  0.05.
FIG. 3. Physical interactions between Foxl2, ER, and cJun. A, 293 FT cells were transfected with Gal4, cJun-Gal4, human ER, and/or mouse
Foxl2 expression vectors and treated for 24 h with vehicle control (ethanol), E2, or tamoxifen. Activation of an upstream activating sequence
(UAS)-E1b-TATA-luciferase reporter is shown. Bars, mean  SEM of two experiments. B, 293FT cells were transfected with human ER and/or HA-
mouse Foxl2 expression vectors and treated for 24 h with vehicle control, E2, or tamoxifen (Tam). Cells lysates were immunoprecipitated (IP) with
anti-HA antibody and immunoblotting (IB) blot was performed for human ER. The background in the representative image was lightened for
clarity of illustration; raw images were used for quantitation. Bars, mean  SEM of four experiments. ADU, Arbitrary densitometric units; RLU,
relative luciferase units. *, P  0.05 (A and B).
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dicating an association of ER with cJun. Importantly,
tamoxifen activation was blocked by coexpression of
Foxl2, confirming that Foxl2 interactswith other proteins
rather thanwithDNAresponse elements to suppressER-
mediated transcriptional activation.
Immunoprecipitation assays were performed to assess
whether Foxl2 and ER interact directly. HA-tagged
Foxl2 was immunoprecipitated using an HA antibody,
followed by Western blot with an antibody for ER.
ERwas not detected after HA immunoprecipitation in
the absence ofHA-Foxl2 (Fig. 3B, top panel, lanes 1 and
2) or absence of transfected ER (lanes 1 and 3). When
both ER and HA-Foxl2 were transfected, ER was
detected in HA-Foxl2 immunoprecipitates, demon-
strating that the two proteins are associated (lane 4).
Levels of detected ER were 2.4-fold higher after ta-
moxifen treatment [Fig. 3B, lane 6 (top panel) and graph
(bottompanel)], suggesting that tamoxifen bindingmay
induce conformational changes in ER that enhance the
interaction with Foxl2. In similar experiments, Foxl2
did not bind to cJun directly (not shown). Thus, Foxl2
appears to bind ER, which is in turn tethered to cJun.
Foxl2 does not alter ER cellular localization
Other members of the Fox family are inactivated by
phosphorylation, which causes them to be exported from
the nucleus (23). The cellular localization of Foxl2 and
ER were examined to assess whether Foxl2 silencing of
ER reflects relocation of Foxl2 to the cytoplasm (Fig. 4).
Immunohistochemical detection is presented in Fig. 4A.
When ER alone is transfected, the localization of the
unliganded receptor is variable, being cytoplasmic (Fig. 4,
i.a) in some cells and nuclear (Fig. 4, i.b) in other cells.
However, after tamoxifen treatment ER localization is
exclusively nuclear (Fig. 4, ii), suggesting that ER in the
nonclassical conformation is transported to and/or re-
tained in the nucleus. Foxl2, by contrast, was found pre-
dominantly in the nucleus (Fig. 4, iii.a and iii.b).
When ER and Foxl2 were coexpressed, unliganded
ER could be detected in the perinuclear region of some
cells (Fig. 4, iv.a), but this expression was much less than
the cytoplasmic staining observed in the absence of Foxl2
(Fig. 4, i.a). In the presence of tamoxifen, both ER and
Foxl2 were observed only in the nucleus (Fig. 4, v). These
data argue against the possibility that Foxl2 suppresses
ER signaling by transporting the receptor from the
nucleus.
Western blot analysis is presented in Fig. 4B and sup-
ports this conclusion. Cells were fractionated into the nu-
clear and cytoplasmic fractions and analyzed for Foxl2
and ER proteins. Consistent with the immunohisto-
chemistry, Foxl2 was located predominantly in the nu-
cleus. Levels were unchanged by cotransfection with
ER alone but were slightly elevated in both the nucleus
and cytoplasm in the presence of ER and tamoxifen.
Levels of ER were higher in the nucleus than in the
cytoplasm and were elevated in both fractions after ta-
moxifen treatment, in the absence or presence of Foxl2
expression. The ratio of ER in the nucleus vs. cyto-
plasmwas relatively stable across treatments, again sug-
gesting that Foxl2 suppression does not involve mod-
ulation of ER nuclear export.
On AP1 sites, Foxl2 is specific for transcriptional
activation
We and others have shown that in addition to tamox-
ifen stimulation, E2 modestly suppresses ER-mediated
transcription at AP1 sites (21). Because this suppression
can be difficult to detect relative to inherently low basal
luciferase activity, repeated independent experiments
FIG. 4. Cellular localization of ER and Foxl2. A, HEK293FT cells were transfected with human ER and/or mouse Foxl2 expression vectors and
treated for 1 h with vehicle control (ethanol) or tamoxifen. Immunodetection of ER (red) and/or Foxl2 (green) is shown; all slides were also stained
for DNA using 4,6-diamino-2-phenylindole (DAPI; blue). B, Cells were transfected as above and treated for 2 h before fractionation
and Western blot using ER and Foxl2 antibodies. Blots containing nuclear and cytoplasmic fractions were also stained for lamin and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively, to confirm equal loading of the lanes.
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were performed to assess whether Foxl2 altered this sup-
pression. Using the AP1 reporter, luciferase activity was
reduced by 50% in the presence of E2 and ER (Fig. 5).
Foxl2 alone had no effect on the AP1 reporter.Moreover,
Foxl2 had no impact on E2 suppression. This finding sug-
gests that Foxl2 action is selective for the complexes as-
sociated with ER stimulation of AP1 reporters.
COX2 is a physiological target of Foxl2/ER
interactions
Microarray experiments using the ERAA mutant,
which selectively acts through tethered transcriptional
pathways, identified the gene for prostaglandin-endoper-
oxide synthase 2 (COX2) as a target of nonclassical ER
signaling (24). COX2 plays an important role in follicle
maturation and ovulation (25), and the proximal COX2
promoter has at least one functional AP-1 site (26), sug-
gesting that COX2 could be a physiological target of
Foxl2/ER interactions.
Using theCOX2promoter, transfectionwith ER con-
ferred a 6.3-fold response to tamoxifen (Fig. 6A), similar
to that seen with the AP1 reporter genes. Foxl2 alone con-
ferred no response to either ligand, but expression of
Foxl2 with ER strongly suppressed tamoxifen stimula-
tion, although a small amount of residual induction
remained.
To confirm that the native COX2 gene is regulated by
Foxl2andER,wemeasuredprotein levels in cells that are
ER-negativebut that expressCOX2(Fig. 6B).Compared
with controls (Fig. 6B, lanes 1 and 2), expression of ER
conferred tamoxifen responsiveness as reflected by in-
creased levels of endogenousCOX2protein (Fig. 6B, lanes
5 and 6), whereas expression of Foxl2 in the absence of
ER was without effect (Fig. 6B, lanes 3 and 4). When
Foxl2was coexpressedwithER, COX2protein returned
to control levels despite the continued presence of tamox-
ifen-activated ER (Fig. 6B, lanes 7 and 8). These data
demonstrate that a native target gene of ER nonclassical
signaling is sensitive to the expression of Foxl2.
Foxl2 binding and transcriptional coactivator
binding colocalize on ER
ER mutants were also tested on the COX2 promoter
to identify the ER domains required for Foxl2 suppres-
sion. The schematic in Fig. 7A illustrates the human ER
domains. The graph in Fig. 7B compares the wild-type
ER to a truncation mutant, termed CDE, in which the
A/B and F domains have been removed. This mutant elim-
inates the activator function (AF) 1 protein interaction
domain but retains DNA binding, ligand binding, and the
AF 2 domain. On the COX2 promoter, tamoxifen induc-
FIG. 5. E2 suppression in the presence of Foxl2. 293FT cells were
transfected with human ER and/or mouse Foxl2 expression vectors
and treated for 24 h with vehicle control (ethanol) or E2. Response
of the AP1-luciferase reporter is shown. Bars, mean  SEM of five
experiments. *, P  0.01.
FIG. 6. Foxl2 regulation of the COX2 promoter and COX2 protein expression. A, 293FT cells were transfected with human ER and/or mouse
Foxl2 expression vectors and treated for 24 h with vehicle control (ethanol), E2, or tamoxifen. Response of the 459COX2-luciferase reporter is
shown. Bars, Mean  SEM of two experiments. *, P  0.05. B, MDA-MB-231 human breast cancer cells were transfected with human ER and/or
mouse Foxl2 expression vectors as indicated and treated for 24 h with tamoxifen. COX2, ER, and -actin were detected by Western blot. RLU,
Relative luciferase units.
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tion and its suppression by Foxl2 are both retained in the
CDE mutant, demonstrating that AF 1 is dispensable for
these actions. These data also demonstrate that coactiva-
tor binding and Foxl2 binding colocalize to the CDE do-
mains of the ER.
We attempted to narrow the active region further using
the ER point mutants I362R and K366D (21). These
mutations are located in ER helix 3, which together with
helices 4, 5, and 12 form a hydrophobic cavity that is
involved in cofactor interactions. Using mammalian two-
hybrid assays, these mutant ERs lost most (I362R) or all
(K366D) of their interaction with steroid receptor coac-
tivator-1 (SRC-1) and glucocorticoid-interacting pro-
tein-1 (GRIP-1; data not shown), twoER transcriptional
cofactors. However, both mutations also abolished ta-
moxifen induction, precluding further analyses of the role
of Foxl2 suppression of tamoxifen-induced transcription
(data not shown).
Discussion
Thecomplexityof estrogen signalinghasbecomeapparent
as studies have revealed additional receptors,multiple ER-
dependent signaling pathways, different ER binding sites
on DNA, and interactions of the ER pathways with those
of other transcription factors (27). These observations
have stimulated interest in nonclassical ER pathways that
do not involve binding of the ER to a classical ERE. In-
cluded in the nonclassical group are membrane-initiated
ER signaling and tethering of ER to other transcription
factors (28), including AP1 proteins, which are bound to
their own DNA response elements.
Foxl2, a forkhead protein, and ER are both critical to
female reproductive development and function (1, 12),
raising the possibility that their actions converge in the
ovary. We initially considered whether Foxl2 might reg-
ulateER expression, or vice versa.However,ERdidnot
alter Foxl2 promoter activity in transfection experiments
(our unpublished data) and expression profiling of human
granulosa cells overexpressing Foxl2 did not identify es-
trogen receptor as a target gene (29). Although these find-
ings do not preclude interdependence of Foxl2 and ER
expression,wealso considered thepossibility that theER
and Foxl2 pathwaysmight intersect at the level of protein-
protein interactions. In pull-down assays, we found that
HA-tagged Foxl2 immunoprecipitates ER. These inter-
actions might be direct between ER and Foxl2, or they
might be indirect through additional proteins. In either
case, thismechanism appears to be highly specific for ER
because the actions of other nuclear receptors (progester-
one receptor, thyroid hormone receptor, peroxisome pro-
liferator activated receptor) were unaffected by coexpres-
sion of Foxl2 (not shown).
Genome-wide screens have identified AP1 as a binding
site for the ER (30), and additional studies have shown
that ER can regulate minimal AP1 promoters (31). Of
note, ER ligands have different effects onAP1 sites when
compared with EREs. E2 stimulates transcription at the
ERE but represses transcription at AP1 sites. Tamoxifen
represses transcription at the ERE but stimulates tran-
scription at AP1 sites. These divergent actions are incom-
pletely understood but have been attributed to the induc-
tion of distinct ER conformations by E2 and tamoxifen
(32), and the subsequent recruitment of alternate groups
of coregulatory factors. Physiologically, selective estrogen
receptor modulators, such as tamoxifen, mediate a spec-
trum of estrogen actions, ranging from agonist to antag-
onist actions (33). For example, tamoxifen acts as an an-
tagonist in the breast but as an agonist in the uterus (34).
In this study,we found that Foxl2 repressed tamoxifen-
mediated stimulation of AP1 regulated promoters. Nota-
FIG. 8. Model for Foxl2 Action. AP1 reporters are shown binding Jun
(J) and Fos (F). Tamoxifen (Tx) bound ER is suggested to interact with
the Jun/Fos complex and to recruit coactivator (CoA) proteins and
stimulate transcription. In the presence of Foxl2, the ER interaction
with coactivator proteins is disrupted, thereby preventing
transcriptional stimulation.
FIG. 7. ER domains required for Foxl2 action. A, Schematic
representation of the domains of the human ER. B, 293FT cells were
transfected with wild-type human ER or a CDE truncation mutant and/or
mouse Foxl2 expression vectors and treated for 24 h with vehicle control
(EtOH, ethanol), E2, or tamoxifen. Response of the459Cox2-luciferase
reporter is shown. Bars, mean SEM of two experiments. *, P 0.05.
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bly, Foxl2 had no effect on E2-stimulated classical EREs
and did not alter E2-mediated repression of AP1 promot-
ers. Thus, the effect of Foxl2 appears to be restricted to the
tamoxifen-induced ER conformation. It is interesting to
consider the potential mechanisms of Foxl2 action. One
possibility would be for Foxl2 to occupy the ER binding
motif on the AP1 proteins. However, this model predicts
that Foxl2 would also alter E2-mediated suppression of
AP1,whichwedidnot observe.A secondpossibility is that
Foxl2 binds to a novel site on the ER and prevents its
interactionwith the AP1 proteins. However, based on our
data, the most likely possibility is that Foxl2 impedes co-
activator binding to ER (Fig. 8). In the presence of ta-
moxifen, helix 12 of the ER obscures a domain that oth-
erwise interacts with coactivator proteins. Thus, for
tetheredAP1signaling tooccur, coactivatorsmust interact
with a domain of the ER that is specifically available in
the tamoxifen-induced conformation. Because the Foxl2
effects are also selective for the tamoxifen-induced con-
formation, it is plausible that the two ER binding part-
ners compete for the same site. This hypothesis is sup-
ported by the colocalization of Foxl2 suppression and
coactivator binding to the CDE core of the ER.
There is mounting evidence that nonclassical signaling
is a key component of ER actions in vivo, particularly in
the reproductive system (35). In the ovary, although the
theca cell is thepredominant site ofER expression, recent
data demonstrate that ER is expressed in mouse granu-
losa cells as well (36). Foxl2 is expressed in the granulosa
cells of ovarian follicles at multiple stages of development
(15). Thus, ER and Foxl2 have the potential to interact
functionally in differentiated somatic cells. The physio-
logical implications of Foxl2 actions through nonclassical
ER signaling are unclear. However, a number of ovarian
candidate genes, including many with AP1 sites, might be
targets of concerted regulation by Foxl2 and ER. For
example, the steroidogenic acute regulatory protein gene,
which is required for steroidogenesis inovarian theca cells,
is regulated by both AP1 proteins (37) and Foxl2 (15).
In an earlier study (24), we identified 268 targets of the
nonclassical pathway in breast cancer cells. A review of
these genes for potential ovarian targets revealed COX2,
which is expressed in granulosa cells (38) and is required
at multiple steps in female reproduction, including ovu-
lation, fertilization, implantation, and decidualization
(39).COX2 is also regulated throughanAP1 site in gastric
cells (26). In the current report, COX2 exhibited all of the
responses collectively observed with the model AP1 re-
porter genes. The COX2 promoter and endogenous
COX2 protein were induced by tamoxifen in the presence
ofER, and this inductionwas suppressedbyFoxl2.Thus,
COX2 may be representative of ovarian genes that are
regulated by ER and Foxl2.
In summary, we have demonstrated that Foxl2 is an
ER interacting protein that can disrupt nonclassical ER
signaling through AP1. We further identified COX2 as a
target of Foxl2 activity, providing a direct link of this
mechanism to ovarian function. Based on the ubiquity of
AP1 action and ER interaction, we predict that other
targets of the Foxl2-ERpathway remain to be discovered
and will provide insight into estrogen action in the ovary.
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